A Review of the Prevalence, Etiology, Diagnosis, and Management of Pediatric Epilepsies in India

Abstract

Pediatric seizures are one of the most common neurological manifestations seen in pediatrics. Unravelling the etiology, timely and appropriate investigations followed by suitable therapies are essential for improving quality of life. During the pandemic, focused group discussions were conducted among 50 pediatric neurologists across five cities in India to gather insights on treatment practices in pediatric epilepsy and to optimize therapeutic strategies and alternative approaches for rational use of antiepileptic medications. These discussions were mainly aimed at reviewing current literature on prevalence, etiology, diagnosis, and management of epilepsy in children and subsequently rationalizing diagnostic and treatment approaches in routine clinical practice. Epileptic encephalopathies comprise of childhood epilepsy with progressive cerebral dysfunction. Genomics plays a vital role in identifying the underlying genetic associations, empowering precision therapy. Currently, the ketogenic diet has become a well-recognized modality for reducing severity of seizures. To overcome the high incidence of adverse effects due to older antiepileptic drugs, newer drugs are being developed to improve ease of use, diminish drug interactions, decrease adverse effects, and identify drugs with unique mechanisms of action. Common lacunae in practice include information gaps, educating parents, or caregivers about rational drug use and ensuring compliance to antiepileptic medications. This article discussed the consensus clinical viewpoint of expert clinicians, as well as insights on optimized treatment of pediatric epilepsies in both infancy and childhood. It also discusses aspects, like reducing drug burden, emerging therapies in the identification of the genetic basis of epilepsies, and targeted therapy alternatives, for pediatric populations in the Indian scenario.

Keywords

pediatric epilepsy - epileptic encephalopathies - ketogenic diet - genomics

Note

The expert group discussion was conducted in association with Abbott Healthcare Pvt. Ltd. This article is based on the views expressed during the expert group discussion. The views expressed and discussed in the meetings and stated in this consensus article are the independent views of the authors and not of Abbott Healthcare Pvt. Ltd.

Publication History

Received: 20 August 2021

Accepted: 04 January 2022

Article published online:
10 March 2022

• References

• 1 Basharat S, Ahsan F, Sikander S, Noreen Shamna. Role of ketogenic diet in pediatric epilepsy. J Psychol Clin Psychiatry 2019; 10: 118-122
• 2 Gossling L, Alix JJP, Stavroulakis T, Hart AR. Investigating and managing neonatal seizures in the UK: an explanatory sequential mixed methods approach. BMC Pediatr 2020; 20 (01) 36
• 3 Udani V. Pediatric epilepsy–an Indian perspective. Indian J Pediatr 2005; 72 (04) 309-313
• 4 Ziobro J, Shellhaas RA. Neonatal seizures: diagnosis, etiologies, and management. Semin Neurol 2020; 40 (02) 246-256
• 5 Jobst BC. Treatment algorithms in refractory partial epilepsy. Epilepsia 2009; 50 (Suppl. 08) 51-56
• 6 Krawiec C, Muzio MR. Neonatal seizure. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2021
• 7 Guidelines on neonatal seizures. Accessed July 6, 2021 at: https://www.ilae.org/files/ilaeGuideline/NeonatalSeizureGuideline-2011-WHO-ILAE.pdf
• 8 van Rooij LGM, van den Broek MPH, Rademaker CMA, de Vries LS. Clinical management of seizures in newborns: diagnosis and treatment. Paediatr Drugs 2013; 15 (01) 9-18
• 9 Sharpe C, Reiner GE, Davis SL. et al; NEOLEV2 INVESTIGATORS. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics 2020; 145 (06) e20193182
• 10 O'Callaghan FJK, Edwards SW, Alber FD. et al; participating investigators. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol 2017; 16 (01) 33-42
• 11 Jain P, Sharma S, Tripathi M. Diagnosis and management of epileptic encephalopathies in children. Epilepsy Res Treat 2013; 2013: 501981
• 12 Pavone P, Polizzi A, Marino SD. et al. West syndrome: a comprehensive review. Neurol Sci 2020; 41 (12) 3547-3562
• 13 Kaushik JS, Patra B, Sharma S, Yadav D, Aneja S. Clinical spectrum and treatment outcome of West Syndrome in children from Northern India. Seizure 2013; 22 (08) 617-621
• 14 Go CY, Mackay MT, Weiss SK. et al; Child Neurology Society, American Academy of Neurology. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2012; 78 (24) 1974-1980
• 15 Sharma S, Kaushik JS, Srivastava K. et al; Association of Child Neurology – Indian Epilepsy Society Expert Committee. Association of Child Neurology (AOCN)-Indian Epilepsy Society (IES) consensus guidelines for the diagnosis and management of West syndrome. Indian Pediatr 2021; 58 (01) 54-66
• 16 Warpe B, Mundhe B, Joshi-Warpe S, Kulkarni A. Cutaneous angiofibroma: a clinching evidence for diagnostic workup of tuberous sclerosis complex. Indian J Dermatopathol Diagn Dermatol 2020; 7: 92-95
• 17 Kunnanayaka V, Jain P, Sharma S, Seth A, Aneja S. Addition of pyridoxine to prednisolone in the treatment of infantile spasms: a pilot, randomized controlled trial. Neurol India 2018; 66 (02) 385-390
• 18 Yıldız EP, Ozkan MU, Uzunhan TA. et al. Efficacy of stiripentol and the clinical outcome in Dravet syndrome. J Child Neurol 2019; 34 (01) 33-37
• 19 Inoue Y, Ohtsuka Y. STP-1 Study Group. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res 2015; 113: 90-97
• 20 Wheless JW, Fulton SP, Mudigoudar BD. Dravet syndrome: a review of current management. Pediatr Neurol 2020; 107: 28-40
• 21 Nabbout R, Copioli C, Chipaux M. et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia 2011; 52 (07) e54-e57
• 22 The Narcotic Drugs and Psychotropic Substances Act. 153-163. 1985 Arrangement of sections. Accessed July 7, 2021 at: https://legislative.gov.in/sites/default/files/A1985-61.pdf
• 23 Samanta D. Cannabidiol: a review of clinical efficacy and safety in epilepsy. Pediatr Neurol 2019; 96: 24-29
• 24 National Organization for Rare Disorders. Lennox-Gastaut syndrome. Accessed July 7, 2021 at: https://rarediseases.org/rare-diseases/lennox-gastaut-syndrome/
• 25 Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci 2018; 39 (03) 403-414
• 26 Expert Committee On Pediatric Epilepsy, Indian Academy Of Pediatrics. Guidelines for diagnosis and management of childhood epilepsy. Accessed July 7, 2021 at: https://www.indianpediatrics.net/aug2009/681.pdf
• 27 Cross JH, Auvin S, Falip M, Striano P, Arzimanoglou A. Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations. Front Neurol 2017; 8: 505
• 28 Auvin S, Hartman AL, Desnous B. et al. Diagnosis delay in West syndrome: misdiagnosis and consequences. Eur J Pediatr 2012; 171 (11) 1695-1701
• 29 Samanta D, Al Khalili Y. Electrical status epilepticus in sleep. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2021
• 30 Arts WFM, Aarsen FK, Scheltens-de Boer M, Catsman-Berrevoets CE. Landau-Kleffner syndrome and CSWS syndrome: treatment with intravenous immunoglobulins. Epilepsia 2009; 50 (Suppl. 07) 55-58
• 31 Hussain SA. Epileptic encephalopathies. Continuum: lifelong learning in neurology. Child Neurol 2018; 24: 171-185
• 32 Pera MC, Randazzo G, Masnada S. et al. Intravenous methylprednisolone pulse therapy for children with epileptic encephalopathy. Funct Neurol 2015; 30 (03) 173-179
• 33 Mellish LC, Dunkley C, Ferrie CD, Pal DK. Antiepileptic drug treatment of Rolandic epilepsy and Panayiotopoulos syndrome: clinical practice survey and clinical trial feasibility. Arch Dis Child 2015; 100 (01) 62-67
• 34 Kessi M, Yan F, Pan L. et al. Treatment for the benign childhood epilepsy with centrotemporal spikes: a monocentric study. Front Neurol 2021; 12: 670958
• 35 Lee YJ, Hwang SK, Kwon S. The clinical spectrum of benign epilepsy with centro-temporal spikes: a challenge in categorization and predictability. J Epilepsy Res 2017; 7 (01) 1-6
• 36 Amrutkar C, Riel-Romero RM. Rolandic epilepsy seizure. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2020: 1-9
• 37 Asadi-Pooya AA, Forouzesh M, Eidi H, Mirzaghafour SE. Levetiracetam versus carbamazepine in treatment of Rolandic epilepsy. Epilepsy Behav 2019; 94: 1-8
• 38 Xiao F, An D, Deng H, Chen S, Ren J, Zhou D. Evaluation of levetiracetam and valproic acid as low-dose monotherapies for children with typical benign childhood epilepsy with centrotemporal spikes (BECTS). Seizure 2014; 23 (09) 756-761
• 39 Liu C, Song M, Wang J. Nightly oral administration of topiramate for benign childhood epilepsy with centrotemporal spikes. Childs Nerv Syst 2016; 32 (05) 839-843
• 40 Aneja S, Jain P. Refractory epilepsy in children. Indian J Pediatr 2014; 81 (10) 1063-1072
• 41 Pasha I, Kamate M, Suresh DK. Safety of lacosamide in children with refractory partial epilepsy. Saudi Pharm J 2015; 23 (05) 556-561
• 42 Heyman E, Lahat E, Levin N, Berkovitch M, Gandelman-Marton R. Preliminary efficacy and safety of lacosamide in children with refractory epilepsy. Eur J Paediatr Neurol 2012; 16 (01) 15-19
• 43 Hebbar M, Mefford HC. Recent advances in epilepsy genomics and genetic testing. F1000Research. 2020; 9: F1000 Faculty Rev-185
• 44 Thodeson DM, Park JY. Genomic testing in pediatric epilepsy. Cold Spring Harb Mol Case Stud 2019; 5 (04) a004135
• 45 Ostrander BEP, Butterfield RJ, Pedersen BS. et al. Whole-genome analysis for effective clinical diagnosis and gene discovery in early infantile epileptic encephalopathy. NPJ Genom Med 2018; 3: 22
• 46 Gonsales MC, Montenegro MA, Soler CV, Coan AC, Guerreiro MM, Lopes-Cendes I. Recent developments in the genetics of childhood epileptic encephalopathies: impact in clinical practice. Arq Neuropsiquiatr 2015; 73 (11) 946-958
• 47 Xiong W, Zhou D. Progress in unraveling the genetic etiology of Rolandic epilepsy. Seizure 2017; 47: 99-104
• 48 Iype M, Koshy KG. Management of infantile spasms: an updated review. Int J Epilepsy 2020; 6: 4-14
• 49 Lin A, Turner Z, Doerrer SC, Stanfield A, Kossoff EH. Complications during ketogenic diet initiation: prevalence, treatment, and influence on seizure outcomes. Pediatr Neurol 2017; 68: 35-39
• 50 Poorshiri B, Barzegar M, Tahmasebi S, Shiva S, Raeisi S, Ebadi Z. The efficacy comparison of classic ketogenic diet and modified Atkins diet in children with refractory epilepsy: a clinical trial. Acta Neurol Belg 2021; 121 (02) 483-487
• 51 Almannai M, Al Mahmoud RA, Mekki M, El-Hattab AW. Metabolic Seizures. Front Neurol 2021; 12: 640371
• 52 Hundallah K, Tabarki B. Treatable inherited metabolic epilepsies. Neurosciences (Riyadh) 2021; 26 (03) 229-235
• 53 Kwon HE, Kim HD. Recent aspects of pediatric epilepsy surgery. J Epilepsy Res 2019; 9 (02) 87-92
• 54 McGuire S, Silva G, Lal D. et al. Safety and efficacy of brivaracetam in pediatric refractory epilepsy: a single-center clinical experience. J Child Neurol 2020; 35 (02) 102-105
• 55 Chang FM, Fan PC, Weng WC, Chang CH, Lee WT. The efficacy of perampanel in young children with drug-resistant epilepsy. Seizure 2020; 75: 82-86
• 56 Ernawati I, Islamiyah WR. Sumarno. How to improve clinical outcome of epileptic seizure control based on medication adherence? A literature review. Open Access Maced J Med Sci 2018; 6 (06) 1174-1179